What is the fair value of Pure Bioscience, Inc (OTC-PURE) stock?

The current fair value estimate for Pure Bioscience, Inc (OTC-PURE) is $0.050. This implies an estimated downside of 18.0% versus the current market price.

Is Pure Bioscience, Inc (OTC-PURE) undervalued or overvalued?

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 18.0% versus the current market price.

How is the financial health of Pure Bioscience, Inc?

The current financial health read for Pure Bioscience, Inc (OTC-PURE) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Pure Bioscience, Inc's next earnings date?

The next earnings date currently listed for Pure Bioscience, Inc (OTC-PURE) is October 30, 2026.

Does Pure Bioscience, Inc (OTC-PURE) pay dividends?

The latest available data indicates no current dividend yield for Pure Bioscience, Inc (OTC-PURE).

What is the market capitalization of Pure Bioscience, Inc?

The current market capitalization listed for Pure Bioscience, Inc is 7.957 M.

What is the enterprise value of Pure Bioscience, Inc?

The current enterprise value listed for Pure Bioscience, Inc is 13.38 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Pure Bioscience, Inc?

The ticker symbol for Pure Bioscience, Inc is OTC-PURE, and the stock is listed on OTC Markets.

Where is Pure Bioscience, Inc (OTC-PURE) listed?

Pure Bioscience, Inc (OTC-PURE) is listed on OTC Markets.

What is the debt-to-total-capital ratio for Pure Bioscience, Inc?

The current debt-to-total-capital ratio listed for Pure Bioscience, Inc is 45.2%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Pure Bioscience, Inc?

The free float listed for Pure Bioscience, Inc is 64.5%. Free float helps investors understand how much of the share base is available for public trading.

Pure Bioscience, Inc (PURE) Fair Value & Stock Analysis

Pure Bioscience, Inc (PURE)

Pure Bioscience, Inc. is a common stock listing on OTC Markets. The company develops and commercializes antimicrobial products designed to address pathogen control and hygiene needs in the United States and abroad. Its technology platform is built around silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent intended to provide residual protection and to be combined with other compounds. PURE Bioscience’s product lineup includes SDC-based disinfecting and sanitizing solutions such as PURE Hard Surface, PURE Control, PURE Multi-Purpose Hi-Foam Floor Cleaner Concentrate, PURE Multi-Purpose Floor Cleaner, and SILVERION, which is used as a raw material ingredient in personal care products. The company serves customers in food processing, food service, hospitality, healthcare, facility care, transportation, and personal care, and distributes its products through end users and third-party distributors. Incorporated in 1992, the company is based in El Cajon, California.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Overall Financial Health	Dividend Yield	Next Earnings Date	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
OTC-PURE	$0.050	-18.0% Downside	Overvalued	Not available	Not available	Weak	0.0%	October 30, 2026	3.2x	7.957 M	13.38 M	45.2%	64.5%	-130.1	80.7%